Willow Biosciences Inc. and SUANFARMA jointly announced execution of a collaboration agreement for a cell line productivity optimization development program for manufacturing a large volume anti-infective Active Pharmaceutical Ingredient (API) through precision fermentation. Through the partnership, SUANFARMA will have access to Willow's proprietary strain optimization technologies to develop a more cost-effective production process. SUANFARMA has engaged Willow to apply its strain engineering technology platform to enable more cost-effective commercial production of the API at SUANFARMA's manufacturing site.